Apixaban

Apixaban
Clinical data
Trade namesEliquis, others
Other namesBMS-562247-01
AHFS/Drugs.comMonograph
MedlinePlusa613032
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability~50%
Protein binding~87%
MetabolismCYP3A4, CYP3A5, CYP1A2 and others
Elimination half-life9–14 h
ExcretionBile duct (75%), kidney (25%)
Identifiers
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.167.332 Edit this at Wikidata
Chemical and physical data
FormulaC25H25N5O4
Molar mass459.506 g·mol−1
3D model (JSmol)
  • O=C5N(c4ccc(N3C(=O)c1c(c(nn1c2ccc(OC)cc2)C(=O)N)CC3)cc4)CCCC5
  • InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
  • Key:QNZCBYKSOIHPEH-UHFFFAOYSA-N

Apixaban, sold under the brand name Eliquis among others, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. It is used as an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a history of prior clots and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth.

Common side effects include bleeding and nausea. Other side effects may include bleeding around the spine and allergic reactions. Use is not recommended during pregnancy or breastfeeding. Use appears to be relatively safe in those with mild kidney problems. Compared to warfarin it has fewer interactions with other medications. It is a direct factor Xa inhibitor.

In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012. It is on the World Health Organization's List of Essential Medicines. In 2024, it was the 25th most commonly prescribed medication in the United States, with more than 21 million prescriptions. It is available as a generic medication, although not in the United States.

Medical uses

Apixaban is indicated for the following:

In the EU, apixaban is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis and pulmonary embolism in adults, and for the prevention of recurrent DVT and PE in adults.

Atrial fibrillation

Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with atrial fibrillation and a CHA2DS2-VASc score ≥ 2. Apixaban may also be considered for men with a CHA2DS2-VASc of 1 after accounting for bleeding risk.

Apixaban and other direct oral anticoagulants (DOACs) (dabigatran, edoxaban and rivaroxaban) are at least as effective as warfarin in preventing stroke or systemic embolism in people with atrial fibrillation not caused by moderate-to-severe mitral stenosis or mechanical heart valves. Compared to warfarin, DOACs are associated with a significantly lower risk of intracranial hemorrhage, with apixaban demonstrating both superior efficacy and safety.

While data are limited for the use of apixaban in people with severely decreased kidney function and those on hemodialysis, studies are investigating its potential as an alternative to standard therapy, vitamin K antagonists. However, optimal dosing in these populations is yet to be determined.

Side effects

Bleeding

Bleeding is a known side effect of apixaban. The likelihood of bleeding increases when it is combined with other medications that affect blood clotting, such as anticoagulants, aspirin, antiplatelet medications, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and nonsteroidal anti-inflammatory drugs (NSAIDs). Large clinical trials, including the ARISTOTLE trial, have shown that these combinations can modestly raise the risk of major bleeding. In clinical practice, healthcare providers carefully assess each patient's individual risk to ensure apixaban is used safely and effectively. In some cases, patients may also report fatigue or tiredness, which can occur as a secondary effect related to anemia or blood loss rather than a direct pharmacological action of apixaban.

Andexanet alfa is a US Food and Drug Administration (FDA) approved antidote for apixaban in people with uncontrolled and life-threatening bleeding events.

Andexanet alfa was voluntarily withdrawn from the U.S. market effective 22 December 2025.

Spinal puncture

Following spinal anesthesia or puncture, people who are being treated with anti-thrombotic agents are at higher risk for developing a hematoma, which causes long-term or permanent paralysis. The risk of this may be increased by using epidural or intrathecal catheters after a surgical operation or from the concurrent use of medicinal agents that affect hemostasis.

Mechanism of action

Apixaban is a highly selective, orally bioavailable, and reversible direct inhibitor of free and clot-bound factor Xa. Factor Xa catalyzes the conversion of prothrombin to thrombin, the final enzyme in the coagulation cascade that is responsible for fibrin clot formation. Apixaban has no direct effect on platelet aggregation, but by inhibiting factor Xa, it indirectly decreases clot formation induced by thrombin.

History

Apixaban was approved for medical use in the European Union in May 2011.

A new drug application (NDA) for the approval of apixaban was submitted to the US Food and Drug Administration (FDA) by Bristol-Myers Squibb (BMS) and Pfizer jointly after the conclusion of the ARISTOTLE clinical trial in 2011. Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012. In March 2014, it was approved for the additional indication of preventing deep vein thrombosis and pulmonary embolism in people who have recently undergone knee or hip replacement. In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism. During its development the drug was known as BMS-562247-01. In 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue.

Society and culture

Economics

In December 2019, the US Food and Drug Administration approved a generic version of apixaban produced jointly by Mylan and Micro Labs. BMS and Pfizer worked quickly to block generics from being created, and in August 2020, they won a patent infringement lawsuit against Sigmapharm, Sunshine Lake, and Unichem, after previously settling patent cases against 25 other companies. In September 2021, a Federal Circuit Court upheld the ruling. The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031.

In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban.

Pfizer reported revenue of US$6.747 billion for Eliquis in 2023.

Apixaban is one of ten medications covered by price negotiations in the US under the Inflation Reduction Act. The negotiations, conducted by the Centers for Medicare & Medicaid Services, apply to pricing for Medicare recipients. The results of the negotiations were announced in August 2024, and Medicare's negotiated price for a 30-day supply of Eliquis is $231, a 56% decrease from the 2023 list price of $521. The pricing is set to take effect in 2026.

References

  1. 1 2 "Apixaban (Eliquis) Use During Pregnancy". Drugs.com. 21 June 2019. Retrieved 13 August 2020.
  2. ↑ "Apibax apixaban 2.5 mg tablet blister pack (428660)". Therapeutic Goods Administration (TGA). 4 December 2024. Retrieved 20 January 2025.
  3. ↑ "Apibax (Nova Pharmaceuticals Australasia Pty Ltd)". Therapeutic Goods Administration (TGA). 14 January 2025. Retrieved 20 January 2025.
  4. ↑ "Eliquis Product information". Health Canada. 1 February 2012. Retrieved 16 February 2025.
  5. ↑ "Eliquis 5 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 3 May 2022. Retrieved 8 October 2022.
  6. 1 2 3 4 "Eliquis- apixaban tablet, film coated Eliquis 30-day starter pack- apixaban kit". DailyMed. 26 November 2019. Retrieved 22 April 2020.
  7. 1 2 3 4 "Eliquis EPAR". European Medicines Agency. 17 September 2018. Retrieved 22 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. 1 2 3 4 5 6 7 8 "Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.
  9. 1 2 3 4 British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 124–125. ISBN 978-0-85711-338-2.
  10. 1 2 3 4 "FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ↑ Hall H (September–October 2020). "How a Drug Is Born". Skeptical Inquirer. Amherst, New York: Center for Inquiry.
  12. ↑ Kiser K (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 978-3-319-54643-8.
  13. ↑ "Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds" (Press release). Pfizer. Archived from the original on 10 September 2015. Retrieved 25 December 2021.
  14. 1 2 3 "Drug Approval Package: Eliquis (apixaban) NDA #202155". U.S. Food and Drug Administration (FDA). 13 February 2013. Archived from the original on 28 June 2013. Retrieved 23 December 2019.
  15. ↑ Organization WH (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  16. ↑ "The Top 300 of 2024". ClinCalc. Archived from the original on 6 November 2026. Retrieved 6 November 2026.
  17. ↑ "Apixaban Drug Usage Statistics, United States, 2014 - 2024". ClinCalc. Retrieved 6 November 2026.
  18. 1 2 "With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now". BioSpace. 6 August 2020. Retrieved 29 November 2021.
  19. 1 2 3 Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978.
  20. ↑ Kjerpeseth LJ, Selmer R, Ariansen I, Karlstad Ø, Ellekjær H, Skovlund E (2019). "Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study". PLOS ONE. 14 (8) e0221500. Bibcode:2019PLoSO..1421500K. doi:10.1371/journal.pone.0221500. PMC 6709911. PMID 31449560.
  21. ↑ Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. (March 2011). "Apixaban in patients with atrial fibrillation". The New England Journal of Medicine. 364 (9): 806–817. doi:10.1056/NEJMoa1007432. PMID 21309657.
  22. ↑ Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P (March 2010). "Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial". Lancet. 375 (9717): 807–815. doi:10.1016/S0140-6736(09)62125-5. PMID 20206776.
  23. ↑ Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM (December 2010). "Apixaban versus enoxaparin for thromboprophylaxis after hip replacement". The New England Journal of Medicine. 363 (26): 2487–2498. doi:10.1056/NEJMoa1006885. PMID 21175312.
  24. ↑ Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. (February 2013). "Apixaban for Extended Treatment of Venous Thromboembolism". The New England Journal of Medicine. 368 (8): 699–708. doi:10.1056/NEJMoa1207541. hdl:2445/178572. PMID 23216615.
  25. ↑ Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, et al. (April 2025). "Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism". The New England Journal of Medicine. 392 (14): 1363–1373. doi:10.1056/NEJMoa2416112. hdl:1887/4290160. PMID 40162636.
  26. ↑ Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre MA, Meneveau N, et al. (March 2025). "Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial". Lancet. 405 (10480): 725–735. doi:10.1016/S0140-6736(24)02842-3. PMID 40023651.
  27. ↑ Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. (March 2019). "New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism". The Medical Journal of Australia. 210 (5): 227–235. doi:10.5694/mja2.50004. PMID 30739331.
  28. ↑ Stevens SM, Woller SC, Baumann Kreuziger L, Doerschug K, Geersing GJ, Klok FA, et al. (August 2024). "Antithrombotic Therapy for VTE Disease". Chest. 166 (2): 388–404. doi:10.1016/j.chest.2024.03.003. PMID 38458430.
  29. ↑ Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. (January 2021). "Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis". European Journal of Vascular and Endovascular Surgery. 61 (1): 9–82. doi:10.1016/j.ejvs.2020.09.023. hdl:10362/147427. PMID 33334670.
  30. ↑ "Atrial fibrillation: diagnosis and management" (PDF). National Institute for Health and Care Excellence. January 2021.
  31. ↑ Joundi RA, Cipriano LE, Sposato LA, Saposnik G, et al. (on behalf of the Stroke Outcomes Research Working Group) (May 2016). "Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score of 1: Systematic Review and Meta-Analysis". Stroke. 47 (5): 1364–1367. doi:10.1161/STROKEAHA.115.012609. PMID 27026630.
  32. ↑ Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. (November 2012). "Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial". Lancet. 380 (9855): 1749–1758. doi:10.1016/S0140-6736(12)60986-6. PMID 23036896.
  33. 1 2 Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. (December 2018). "Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review". Annals of Internal Medicine. 169 (11): 774–787. doi:10.7326/M18-1523. PMC 6825839. PMID 30383133.
  34. 1 2 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. (September 2009). "Dabigatran versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 361 (12): 1139–1151. doi:10.1056/NEJMoa0905561. hdl:11343/221723. PMID 19717844.
  35. 1 2 Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. (September 2011). "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation". The New England Journal of Medicine. 365 (10): 883–891. doi:10.1056/NEJMoa1009638. PMC 3860773. PMID 21830957.
  36. ↑ Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. (November 2012). "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial". European Heart Journal. 33 (22): 2821–2830. doi:10.1093/eurheartj/ehs274. PMID 22933567.
  37. 1 2 Fernandez S, Lenoir C, Samer C, Rollason V (October 2020). "Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports". Pharmacology Research & Perspectives. 8 (5) e00647. doi:10.1002/prp2.647. ISSN 2052-1707. PMC 7507549. PMID 32881416.
  38. ↑ Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. (June 2016). "Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial". BMJ. 353 i2868. doi:10.1136/bmj.i2868. ISSN 1756-1833. PMC 4908974. PMID 27306620.
  39. ↑ Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. (August 2011). "Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome". The New England Journal of Medicine. 365 (8): 699–708. doi:10.1056/NEJMoa1105819. hdl:2066/95648. PMID 21780946.
  40. ↑ Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. (March 2011). "Apixaban in Patients with Atrial Fibrillation". The New England Journal of Medicine. 364 (9): 806–817. doi:10.1056/NEJMoa1007432. PMID 21309657.
  41. ↑ Chang KH, Chen CM, Wang CL, Tu HT, Huang YT, Wu HC, et al. (February 2022). "Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants". Frontiers in Aging Neuroscience. 14 791285. doi:10.3389/fnagi.2022.791285. ISSN 1663-4365. PMC 8855103. PMID 35185526.
  42. ↑ Rahman AA, Platt RW, Beradid S, Boivin JF, Rej S, Renoux C (March 2024). "Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding". JAMA Network Open. 7 (3): e243208. doi:10.1001/jamanetworkopen.2024.3208. ISSN 2574-3805. PMC 10960200. PMID 38517440.
  43. ↑ "Does Apixaban Cause Fatigue? Causes and Considerations". Canada Pharmacy Pro. Retrieved 21 April 2026.
  44. ↑ "Andexxa- andexanet alfa injection, powder, lyophilized, for solution". DailyMed. 8 January 2019. Retrieved 23 December 2019.
  45. ↑ "Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)". U.S. Food and Drug Administration (FDA). 31 December 2018. Archived from the original on 29 May 2020. Retrieved 22 April 2020.
  46. ↑ Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. (February 2013). "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects". British Journal of Clinical Pharmacology. 75 (2): 476–487. doi:10.1111/j.1365-2125.2012.04369.x. PMC 3558798. PMID 22759198.
  47. ↑ Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978. S2CID 43262809.
  48. ↑ Cada DJ, Levien TL, Baker DE (June 2013). "Apixaban". Hospital Pharmacy. 48 (6): 494–509. doi:10.1310/hpj4806-494. PMC 3839491. PMID 24421512.
  49. 1 2 "FDA-Approved Drugs: Eliquis (apixaban)". U.S. Food and Drug Administration (FDA). Archived from the original on 17 February 2017. Retrieved 23 December 2019.
  50. ↑ Neale T (14 March 2014). "FDA OKs Apixaban for DVT Prevention". MedPage Today. Retrieved 17 September 2015.
  51. ↑ "U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy" (Press release). Pfizer. 21 August 2014. Retrieved 26 February 2016.
  52. ↑ "Apixaban". PubChem, US National Library of Medicine. 27 August 2022. Retrieved 2 September 2022.
  53. 1 2 "FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis". Business Medical Dialogues. New Delhi, India: Minerva Medical Treatment. 24 December 2019. Retrieved 24 December 2019.
  54. ↑ "2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). 5 August 2020. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  55. ↑ "Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc". JD Supra. Retrieved 30 November 2021.
  56. ↑ "Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug". BioPharma Dive. Retrieved 30 November 2021.
  57. ↑ "Federal Circuit Crystallizes BMS' Apixaban District Court Win". The National Law Review. Retrieved 30 November 2021.
  58. ↑ Levy S (1 August 2022). "Apotex offers generic Eliquis in Canada". Drugstore News. Retrieved 2 September 2022.
  59. ↑ "First Generic Alternative to Eliquis Now Available in Canada". Apotex (Press release). 20 July 2022.
  60. ↑ "Pfizer's year in review". Pfizer 2023 Annual Report. 31 December 2023. Retrieved 30 December 2024.
  61. ↑ "Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026". CMS. 15 August 2024. Retrieved 30 December 2024.
  62. ↑ Lovelace Jr B (15 August 2024). "Medicare announces lower prices on 10 common, high-cost drugs". NBC News. Retrieved 21 August 2024.
  63. ↑ "Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices" (PDF). Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. 15 August 2024.